Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRACE-VAP: Gram Stain-guided Antibiotics for Ventilator-Associated Pneumonia
NCT03506113Phase 4Completed
- Sponsor
- Osaka General Medical Center
- Start
- Apr 2018
- Primary completion
- Jun 2020
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial in ventilator-associated pneumonia (VAP) (2 arms), sponsored by Osaka General Medical Center. Primary endpoint: Clinical cure of VAP at 22 days. Started Apr 2018; status: completed.
02
Conditions
ventilator-associated pneumonia (VAP)
Beyond the preview
Go deeper on NCT03506113.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03506113.